ASAH1-AS1: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: ASAH1-AS1

NCBI ID: G101929066

ASAH1-AS1

Other Name(s): ASAH1 antisense RNA 1, transcript variant 1 | ASAH1 antisense RNA 1

ASAH1-AS1: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain can have a significant impact on an individual's quality of life and overall prognosis. As such, there is an urgent need for new treatments that can effectively alleviate chronic pain. In recent years, significant progress has been made in the development of new pain medications, but many of these drugs have limited efficacy and potential adverse effects.

ASAH1-AS1, a transcribed RNA molecule, has been identified as a potential drug target and biomarker for chronic pain. In this article, we will explore the ASAH1-AS1 molecule, its function in pain signaling, and its potential as a drug target.

ASAH1-AS1 Molecule and Its Functions

ASAH1-AS1 is a non-coding RNA molecule that is expressed in various tissues and cell types. It is a part of the intergenic RNA (ISR) pool and has been identified as a potential drug target and biomarker for chronic pain.

The ASAH1-AS1 molecule is characterized by its unique structure and biology. It consists of 19 exons that encode a protein coding gene. The protein encoded by ASAH1-AS1 has a calculated molecular weight of 12.9 kDa and a predicted localization in the cell nucleus.

ASAH1-AS1 has been shown to play a significant role in pain signaling. It is a key molecule in the inflammatory response and has been involved in the regulation of pain perception.

ASAH1-AS1 has been shown to regulate the activity of several pain-related genes, including heat-regulated gene expression (HRE)22, nuclear factor kappa B (NF-kappa-B), and calcitonin gene-related peptide (CGP). These genes are involved in the regulation of pain perception, inflammation, and cellular signaling.

ASAH1-AS1 has also been shown to interact with several protein molecules, including the nuclear protein p63 and the cytoplasmic protein TDP-45. These interactions may play a role in the regulation of pain perception and the regulation of cellular signaling.

Drug Target Potential

ASAH1-AS1's potential as a drug target is based on its involvement in pain signaling. The development of new pain medications has been a major focus of research in the past few decades, but many of these drugs have limited efficacy and potential adverse effects.

ASAH1-AS1 may be a promising drug target due to its unique structure and biology. Its regulation of pain-related genes and its interactions with other proteins suggest that it may be a good candidate for new pain medications.

Biomarker Potential

ASAH1-AS1 has also been shown to be a potential biomarker for chronic pain. The development of new biomarkers for chronic pain has been a major focus of research in the past few decades, and ASAH1-AS1 may be one of these biomarkers.

ASAH1-AS1 has been shown to be involved in the regulation of pain perception and the regulation of cellular signaling. Its involvement in these processes suggests that it may be a good candidate for use as a biomarker for chronic pain.

Conclusion

ASAH1-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for chronic pain. Its unique structure and biology, as well as its involvement in pain signaling and cellular signaling, make it a promising candidate for new pain medications and biomarkers. Further research is needed to determine its potential as a drug target and biomarker for chronic pain.

Protein Name: ASAH1 Antisense RNA 1

The "ASAH1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASAH1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets